A new model might improve quality of life and prevent over-treatment
Annual prostate-specific antigen screening among Black men might help reduce disparities in prostate cancer mortality, study findings suggest.
The application is supported by findings from the phase 3 PROpel trial.
The breakthrough device designation is intended to expedite the development and regulatory review of the treatment system in prostate cancer.
To assist in making a cancer diagnosis, Bot Image’s machine learning program produces a colorized map of normal and abnormal prostate tissue.
Patients with hormone-sensitive prostate cancer who received darolutamide in combination with docetaxel experienced superior overall survival and time-to-pain progression benefit.